Neuroprotection and the ischémie cascade

CNS Spectrums

Volumn 5, Issue 3, 2000, Pages 52-58

  Felberg, Robert A ^a   Burgin, W Scott ^a   Grotta, James C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ABCIXIMAB; ADENOSINE RECEPTOR STIMULATING AGENT; AMPA RECEPTOR ANTAGONIST; ANCROD; ANTITHROMBOCYTIC AGENT; APTIGANEL; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM ANTAGONIST; CITICOLINE; DIASPIRIN CROSSLINKED HEMOGLOBIN; ELIPRODIL; FIBRINOLYTIC AGENT; FOSPHENYTOIN SODIUM; GANGLIOSIDE GM1; GLUTAMATE RECEPTOR ANTAGONIST; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LUBELUZOLE; MAGNESIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICARDIPINE; NIMODIPINE; POTASSIUM CHANNEL AFFECTING AGENT; PROTECTIVE AGENT; PROUROKINASE; SCAVENGER; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN PROTECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; FIBRINOLYTIC THERAPY; HUMAN; HYPERBARIC OXYGEN; INDUCED HYPOTHERMIA; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034019505     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900012967     Document Type: Article

References (74)

1. Pulsinelli WA, Brierly JB, Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neural. 1982;ll:491-498.
2. Kirino T, Tamura A, Sano K. Delayed neuronal death in the rat hippocampus following transient forebrain ischemia. Ada Neuropathol (Bed). 1984;64:139-147.
3. Petito CK, Pulsinelli WA. Delayed neuronal recovery and neuronal death in rat hippocampus following severe cerebral ischemia: possible relationship to abnormalities in neuronal processes. / Cereb Blood Flow Metab. 1984;4:194-205.
4. Petito CK, Pulsinelli WA. Sequential development of reversible and irreversible neuronal damage following cerebral ischemia. / Neuropathol Exp Neural. 1984;43:141-153.
5. Petito CK, Feldman E, Pulsinelli WA, Plum F. Delayed hippocampal damage in humans following cardiorespiratory arrest. Neurology. 1987;37:1281-1286.
6. Symon L, Branston NM, Strong AJ, et al. The concepts of threshold ischaemia in relation to brain structure and function. JClinPathol. 1997;30(suPPl 11):149-154.
7. Astrup J, Symon L, Siesjö BK. Thresholds in cerebral ischemia: the ischémie penumbra. Stroke. 1981;12:723-725.
8. Memezawa H, Smith M, Siesjö BK. Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats. Stroke. 1992;23:552-559.
9. Siesjö BK. Pathophysiology and treatment of focal cerebral ischemia, II: mechanisms of damage and treatment. JNeurosurg. 1992;77:337-354.
10. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosd. 1990;13:171-182.
11. Cheung JY, Bonventre JV, Malis Cd, Leaf A. Calcium and ischémie injury. N Engl J Med. 1986;314:1670-1676.
12. Rubin E, Farber JL. Cell injury. In: Rubin E, Farber JL, eds. Pathology. Philadelphia, Pa: J.B. Lippencott Company; 1988:4-33.
13. Auer RN. Histopathology of cerebral ischemia. In: Ginsburg MD, Bogousslavsky J, eds. Cerebroiascular Disease: Pathophysiology, Diagnosis, and Management. Maiden, Mass: Blackwell Science; 1998:90-101.
14. Garcia JH. Mechanisms of cell death in ischemia. In: Caplan LR, ed. Brain Ischemia: Basic Concepts and Clinical Relevance. London, UK: Springer-Verlag; 1995:7-18.
15. Ginsberg MD. Neuroprotection in brain ischemia, I: an update. The Neuroscientist. 1995;1:95-103.
16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischémie stroke. W Engl J Med. 1995;333:1581-1587.
17. Yang G, Betz L. Reperfusion-induced injury to the blood brain barrier after middle cerebral artery occlusion in rats.&roA-e. 1994;25:1658-1664.
18. Grotta JC, Chiu D. Pharmacologie modification of acute cerebral ischemia. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: Pathophysiology, Diagnosis, and Management. 3rd ed. Philadelphia, Pa: Churchill Livingstone; 1998:1079-1088.
19. Horikawa Y, Naruse S, Hirakawa K, et al. In vivo studies of energy metabolism in experimental cerebral ischemia using topical magnetic resonance: changes in " Pnuclear magnetic resonance spectra compared with electroencephalograms and regional cerebral blood flow. y Cereb Blood Flow Metab. 1985;235-240.
20. Ricci PE Jr. Proton MR spectroscopy in ischémie stroke and other vascular disorders. Neuroimaging Clin N Am. 1998;8:881-900.
21. Kohno K, Hoehn-Berlage M, Mies G, Bach T, Hossmann KA. Relationship between diffusion weighted MR images, cerebral blood flow, and energy state in experimental brain infarction. Magn Reson Imaging. 1995;13:73-80.
22. von Kummer R. Ischémie stroke and tissue hypodensity on computed tomography. Stroke. 1999;30:1974.
23. Butcher SP, Bullock R, Graham DI, et al. Correlation between amino acid release and neuropathological outcome in rat brain following middle cerebral arter)- occlusion. Stroke. 1990;21:1727-1733.
24. Benveniste H, Drejer J, Schousboe A, et al. Elevation of extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. / Neurochem. 1984;43:1369-1374.
25. Pellegrini-Giampietro DE, Zukin RS, Bennett MVL, Cho S, Pulsinelli WA. Switching glutamate receptor subunit gene in CA1 subfield of hippocampus following global ischemia in rats. Proc NatlAcadSci USA. 1992;89:10499-10503.
26. Greenamyre JT. The role of glutamate in neurotransmission in neurological disease. Arch Neural. 1986;43:1058-1063.
27. MacDermott AB, Mayer ML, Westbrook GL. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurons. Nature. 1986;321:529-522.
28. Rothman SM. Excitotoxins: possible mechanisms of action. Ann NYAcad Sci. 1992;648:132-139.
29. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. A' Engl J Med. 1994;330:613-622.
30. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neural. 1986;19:105-111.
31. Sl.Schoepp DD, Conn PJ. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmocol Sci. 1993;14:13-20.
32. Choi DW. Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev. 1990;2:105-147.
33. Siesjo BK, Agardh C, Bengtsson F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev. 1989;1:165-211.
34. Siesjo BK, Bengtsson F. Calcium fluxes, calcium antagonists, and calcium related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis. }Cereb Blood Flow Metab. 1989;9:127-140.
35. Lee K, Frank S, Vanderklish P, Aral A, Lynch G. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc Nail Acad Sri USA. 1991:88:7233-7237.
36. Roberts-Lewis JM, Savage MJ, Marcy VR, Pinsker LR, Siman R. Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischémie gerbil brain. J Neumsci. 1994;14:3934-3944.
37. Hong S-C, Goto Y, Lanzino G, Soleau S, Kassell NF, Lee KS. Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia. Stroke. 1994;24:663-669.
38. Traystman RJ, Kirsch JR, Koehler RC. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol. 1991;71:1185-1195.
39. Rice-Evans CA, Diplock AT. Current status of antioxidant therapy. Free Radie Biol Med. 1993;15:77-%.
40. Wise RJS, Bemardi S, Frackowski RSJ, et al. Serial observations on the pathophysiology of acute stroke: the transition from ischaemia to infarction as reflected in regional oxygen extraction. Brain. 1983;106:197-222.
41. Heiss W-D, Huber M, Fink GR, et al. Progressive derangement of periinfarct viable tissue in acute ischémie stroke. / Cereb Blood Flow Metab. 1992;12:193-203.
42. Baird AE, Benefield A, Schlaug G, et al. Enlargement of human cerebral ischémie lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neural. 1997;41:581-589.
43. Hakim AM, Evans AC, Berger L, et al. The effect of nimodipine on the evolution of human cerebral infarction studied by PET. J Cereb Blood Flow Metab. 1989;9:523-534.
44. Shinohara M, Dollinger B, Brown G, et al. Cerebral glucose utilization: local changes during and after recovery from spreading cortical depression. Science. 1979;203:188-190.
45. Kocher M. Metabolic and hemodynamic activation of postischemic rat brain by cortical spreading depression. J Cereb Blood Flow Metab. 1990;10:564-571.
46. Mies G, lijama T, Hossman K-A. Correlation between periinfarct DC shifts and ischémie neuronal damage in the rat. Neuroreport. 1993;4:709-711.
47. The Hemodilution in Stroke Study Group. Hypervolemic hemodilution treatment of acute stroke: results of a randomized multicenter trial using pentastarch. Stroke. 1989;20:317-323.
48. Feuerstein GZ, Wang X, Barone FC. Inflammatory mediators and brain injury: the role of cytokines and chemokines in stroke and CNS diseases. In: Ginsburg MD, Bogousslavsky J, eds. Cerebral-oscular Disease: Pathophysiolog); Diagnosis, and Management. Maiden, Mass: BlackweU Science; 1998:507-531.
49. Gage FH. Stem cells of the central nervous system. Curr Opin Keurobiol. 1998;8:671-676.
50. Kirschner P, Henshaw R, Weise J, et al. Basic fibroblast growth factor protects against excitotoxicity and chemical hypoxia in both neonatal and adult rats. J Cereb Blood Flow Metab. 1995;15:619-623.
51. Aronowski J, Ostrow P, Samways E, Strong R, Zivin J, Grotta J. Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats. Stroke. 1994;25:2235-2240.
52. Ginsberg MD. Neuroprotection in brain ischemia, II: an update. The Neuroscientist. 1995;1:164-175.
53. Clifton G, Alien S, Barrodale P, et al. A phase II study of moderate hypothermia in severe brain injury. J Neurotrauma. 1993;10:263-271.
54. Bernard SA, Jones BM, Hörne MK. Clinical trial of induced hypothermia in comatose survivors of out-of-hospital cardiac arrest. Ann EmergMed. 1997;30:146-153.
55. Felberg RA, Hickenbottom SJ, Burgin WS, Kirn Y, Persse DE, Grotta JC. Moderate induced hypothermia following cardiac arrest: a safety and feasibility trial (abstract). Stroke. 2000;1:284.
56. Schwab S, Schwarz S, Spranger M, Keller E, Bertram M, Hacke W. Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction. Stroke. 199829:2461-2466.
57. del Zoppo GJ, Higashida RT, Furlan A], Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant prourokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998;29:4-11.
58. Atkinson RP. Ancrod in the treatment of acute ischémie stroke: a review of clinical data. Cerebrorasc Dis. 1998;8(suppl l):23-28.
59. Grolta JC. Acute stroke therapy at the millennium: consummating the marriage between the laboratory and bedside: the Feinberg lecture. Stroke. 1999;30:1722-1728.
60. Hacke W, Kaste M, Fieschi et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischémie stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
61. ol.Tettenhom D, Dycka J. Prevention and treatment of delayed ischémie dysfunction in patients with aneurysmal subarachnoid hemorrhage. Stroke. 1990;21(suppl 4):85-89.
62. Mohr J, Orgogozo J, Harrison M, et al. Meta-analysis of oral nimodipine trials in acute ischémie stroke. CerebrovascDu. 1994;4:197-201.
63. Grotta J. The current status of neuronal protective therapy: why have all the neuronal protective drugs worked in animals but none so far in stroke patients? Cerebroiasc Dis. 1994;4:115-120.
64. Arrowsmith JE, Harrison MJ, Newman SP, Stygall J, Timberlake N, Pugsley WB. Neuroprotection of the brain during cardiopulmonary bypass: a randomized trial of remacemide during coronary artery bypass in 171 patients. Stroke, 1998;29:2357-2362.
65. Uematsu D, Araki N, Greenberg JH, Sladky J, Reivich M. Combined therapy with MK-801 and nimodipine for protection of ischémie brain damage. Neurology. 1991;41:88-94.
66. Globus MY-T, Dietrich WD, Busto R, Valdes I, Ginsburg MD. The combined treatment with a dopaminé D-l antagonist (SCH-23390) and NMDA receptor blocker (MK-801) dramatically protects against ischemia-induced hippocampal damage. J Cereb Blood Flow Metab. 1989;9(suppl 1):S5.
67. Zivin JA. Therapy of embolie stroke with tissue plasminogen activator plus a glutamate antagonist. Neurology. 1989;39(suppl 1):372.
68. Sereghy T, Overgaard K, Boysen G. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolie stroke in rats. Stroke. 1993;24:1702-1708.
69. Frazee JG, Jordan SE, Dion JE, et al. Ischémie brain rescue by transvenous perfusion in baboons with venous sinus occlusion. Stroke. 1990;21:87-93.
70. Spilker J, Kongable G, Barch C, et al. Using the NIH Stroke Scale to assess stroke patients: the NINDS rt-PA Stroke Study Group. J Neurosci Nurs. 1997;29:384-392.
71. Kreiger DW, Demchuk AM, Kasner SE, Jauss M, Hanston L. Early clinical and radiological predictors of fatal brain swelling in ischémie stroke. Stroke. 1999;30:287-292.
72. 72.de Haan R, Limburg M, Bossuyt P, van der Meulen J, Aaronson N. The clinical meaning of Rankin "handicap" grades after stroke. Stroke. 1995;26:2027-2030.
73. Wolfe CD, Taub NA, Woodrow EJ, Burney PC. Assessment of scales of disability and handicap for stroke patients. Stroke. 1991;22:1242-1244.
74. Suiter G, Steen C, De Keyser J. Use of Barthel index and modified Rankin scale in acute stroke trials. Stroke. 1999;30:1538-1541.